Making Best Use of the Newer Antifungal Agents

Drug Benefit Trends

Volumn 16, Issue 3, 2004, Pages 131-132+142

  McKinsey, David S ^a  

^a UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

Author keywords

Amphotericin B; Caspofungin; Fluconazole; Flucytosine; Infection, fungal; Itraconazole; Voriconazole

Indexed keywords

AMPHOTERICIN B CHOLESTEROL SULFATE; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ANTIFUNGAL AGENT; CARBAMAZEPINE; CASPOFUNGIN; CISAPRIDE; CYCLOSPORIN; DIGOXIN; ECHINOCANDIN B; FLUCONAZOLE; FLUCYTOSINE; FOSPHENYTOIN SODIUM; ISONIAZID; ITRACONAZOLE; KETOCONAZOLE; OMEPRAZOLE; PHENYTOIN; RAPAMYCIN; RIFAMPICIN; SULFONYLUREA DERIVATIVE; TACROLIMUS; TERBINAFINE; VORICONAZOLE; WARFARIN;

ALOPECIA; ANEMIA; ANTIFUNGAL ACTIVITY; ASPERGILLOSIS; BONE MARROW SUPPRESSION; CANDIDIASIS; CHILL; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CRYPTOCOCCOSIS; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG CLASSIFICATION; DRUG EFFICACY; DRUG FORMULATION; DRUG INDICATION; DRUG INFUSION; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG SENSITIVITY; EYE TOXICITY; FEBRILE NEUTROPENIA; FEVER; FUNGAL MENINGITIS; GASTROINTESTINAL TOXICITY; HEALTH CARE COST; HUMAN; HYPOKALEMIA; HYPOMAGNESEMIA; HYPOXIA; KIDNEY FAILURE; KIDNEY TUBULE ACIDOSIS; LIVER FUNCTION TEST; MONOTHERAPY; MYCOSIS; NAUSEA; NEPHROTOXICITY; PERIPHERAL EDEMA; PHLEBITIS; PHOTOSENSITIVITY DISORDER; RASH; REVIEW; URINARY TRACT INFECTION; VISUAL IMPAIRMENT; XEROSIS;

EID: 1642397223     PISSN: 10805826     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (27)

1. Pfaller M, Messer S, Hollis R, et al. In vitro activities of ravuconazole and voriconazole compared with those of four approved systemic antifungal agents against 6,970 clinical isolates of Candida spp. Antimicrob Agents Chemother. 2002; 46:1723-1727.
2. Wingard J, Kubilis P, Lee L, et al. Clinical significance of nephrotoxicity in patients treated with amphotericin B for suspected or proven aspergillosis. Clin Infect Dis. 1999;29:1402-1407.
3. Walsh T, Heimenz J. Lipid formulations of amphotericin B: recent developments in improving the therapeutic index of a gold standard. Infect Dis Clin Pract. 1998;7(suppl 1):16-17.
4. Wingard J, White M, Anaissie E, et al. A randomized, double-blind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia. Clin Infect Dis. 2000;31:1155-1163.
5. Bowden R, Chandrasekar P, White M, et al. A double-blind, randomized, controlled trial of amphotericin B colloidal dispersion versus amphotericin B for treatment of invasive aspergillosis in immunocompromised patients. Clin Infect Dis. 2002;35:359-366.
6. Pappas P, Kauffman C, Perfect J, et al. Alopecia associated with fluconazole therapy. Ann Intern Med. 1995;123:354-357.
7. van der Horst C, Saag M, Cloud G, et al. Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome. N Engl J Med. 1997;337:15-21.
8. Walsh TJ, Finberg RW, Arndt C, et al. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. N Engl J Med. 1999;340:764-771.
9. Walsh TJ, Pappas P, Winston DJ, et al. Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N Engl J Med. 2002;346:225-234.
10. Walsh T, Pappas P, Winston D. Voriconazole versus liposomal amphotericin B for empirical antifungal therapy. N Engl J Med. 2002;366:1745-1747.
11. Walsh T, Sable C, Depauw B, et al. A randomized, double blind, multicenter trial of caspofungin vs liposomal amphotericin B therapy for persistently febrile neutropenic patients. In: Program and abstracts of the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy; September 14-17, 2003; Chicago. Abstract M-1761.
12. Rex J, Bennett J, Sugar A, et al. A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. N Engl J Med. 1994;331:1325-1330.
13. Rex J, Pappas P, Karchmer A, et al. A randomized and blinded multicenter trial of high-dose fluconazole plus placebo versus fluconazole plus amphotericin B as therapy for candidemia and its consequences in nonneutropenic patients. Clin Infect Dis. 2003;36:1221-1228.
14. Mora-Duarte J, Betts R, Rotstein C, et al. Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med. 2002;347: 2020-2029.
15. Sobel J, Kauffman C, McKinsey D, et al. Candiduria: a randomized, double-blind study of treatment with fluconazole and placebo. Clin Infect Dis. 2000;30:19-24.
16. Ally R, Schurmann D, Kreisel W, et al. A randomized, double-blind, double-dummy, multicenter trial of voriconazole and fluconazole in the treatment of esophageal candidiasis in immunocompromised patients. Clin Infect Dis. 2001;33:1447-1454.
17. Arathoon EG, Gotuzzo E, Noriega L, et al. Randomized, double blind, multicenter study of caspofungin versus amphotericin B for the treatment of oropharyngeal and esophageal candidiasis. Antimicrob Agents Chemother. 2002;46:451-457.
18. Kartsonis M, DiNubile MJ, Bartizal K, et al. Efficacy of caspofungin in the treatment of esophageal candidiasis refractory to fluconazole. J Acquir Immune Defic Syndr. 2002;31:183-187.
19. Saag M, Cloud G, Graybill J, et al. A comparison of itraconazole versus fluconazole as maintenance therapy for AIDS-associated cryptococcal meningitis. Clin Infect Dis. 1999;28:291-296.
20. Sharkey P, Graybill J, Johnson E, et al. Amphotericin B lipid complex compared with amphotericin B in the treatment of cryptococcal meningitis in patients with AIDS. Clin Infect Dis. 1996; 22:315-321.
21. Leenders AC, Reiss P, Portegies P, et al. Liposomal amphotericin B (AmBisome) compared with amphotericin B both followed by oral fluconazole in the treatment of AIDS-associated cryptococcal meningitis. AIDS. 1997;11:1463-1471.
22. Lin SJ, Schranz J, Teutsch SM. Aspergillosis case-fatality rate: systematic review of the literature. Clin Infect Dis. 2001;32:358-366.
23. Walsh TJ, Hiemenz JW, Seibel NL, et al. Amphotericin B lipid complex for invasive fungal infections: analysis of safety and efficacy in 556 cases. Clin Infect Dis. 1998;626:1383-1396.
24. Ellis M, Spence D, de Pauw B, et al. An EORTC international multicenter randomized trial (EORTC number 19923) comparing two dosages of liposomal amphotericin B for treatment of invasive aspergillosis. Clin Infect Dis. 1998;27:1406-1412.
25. Denning D, Ribaud P, Milpied N, et al. Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clin Infect Dis. 2002; 34:563-571.
26. Herbrecht R, Denning D, Patterson T, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med. 2002;347:408-415.
27. Cancidas [package insert]. Whitehouse Station, NJ: Merck & Co, Inc; 2001.